SBL
MRNA icon

Sargent Bickham Lagudis’s Moderna MRNA Stock Holding History

Sargent Bickham Lagudis’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$141K Buy
786
+100
+15% +$16.4K 0.01% 304
2022
Q3 		$81K Hold
686
– – 0.01% 342
2022
Q2 		$98K Hold
686
– – 0.01% 324
2022
Q1 		$118K Buy
686
+10
+1% +$1.68K 0.01% 312
2021
Q4 		$172K Sell
676
-107
-14% -$31.3K 0.01% 259
2021
Q3 		$301K Buy
783
+102
+15% +$37.6K 0.02% 207
2021
Q2 		$160K Sell
681
-7
-1% -$1.25K 0.01% 282
2021
Q1 		$90K Sell
688
-7
-1% -$1.01K 0.01% 349
2020
Q4 		$73K Buy
695
+13
+2% +$1.31K 0.01% 366
2020
Q3 		$48K Buy
682
+75
+12% +$5.23K ﹤0.01% 387
2020
Q2 		$39K Hold
607
– – ﹤0.01% 386
2020
Q1 		$18K Hold
607
– – ﹤0.01% 483
2019
Q4 		$12K Hold
607
– – ﹤0.01% 594
2019
Q3 		$10K Hold
607
– – ﹤0.01% 563
2019
Q2 		$9K Hold
607
– – ﹤0.01% 602
2019
Q1 		$12K Buy
+607
New +$11.3K ﹤0.01% 587

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sargent Bickham Lagudis's MRNA Position: Q4 2022 in Review

Sargent Bickham Lagudis increased its Moderna (MRNA) stake by 15% in Q4 2022, buying an estimated $16.4K and bringing the position to 786 shares worth $141K. The position accounts for 0.01% of the portfolio, ranked #304.

Sargent Bickham Lagudis first reported a position in MRNA in Q1 2019 and has held it in 16 quarters since. The position peaked at $301K in Q3 2021. 1,071 funds tracked by Wall St. Rank hold MRNA as of Q4 2022.

  • Sargent Bickham Lagudis held 786 shares of Moderna worth $141K as of Q4 2022.
  • Sargent Bickham Lagudis bought 100 Moderna shares in Q4 2022, an estimated $16.4K.
  • Moderna made up 0.01% of Sargent Bickham Lagudis's portfolio in Q4 2022, its #304 holding.
  • Sargent Bickham Lagudis first reported a position in Moderna in Q1 2019 and has held it in 16 quarters since.
  • Sargent Bickham Lagudis's Moderna position peaked at $301K in Q3 2021.
  • 1,071 funds tracked by Wall St. Rank held Moderna as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.